CLINICAL TRIAL: ACR16 VERSUS PLACEBO FOR THE SYMPTOMATIC TREATMENT OF HUNTINGTON

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。所列机构为 中心，不一定是研究者的机构。 评价ACR 16作为亨廷顿病（HD）对症治疗的有效性，并研究ACR 16的量效关系。主要目的是评估ACR 16对HD受试者自主运动功能的影响。次要目的是评估12周治疗时ACR 16对临床总体印象变化（CGI-C）、认知功能、行为以及抑郁和焦虑症状的影响;此外还评估其安全性和耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To evaluate the effectiveness of ACR16 as a symptomatic treatment for Huntington disease (HD) and to investigate the dose-response relationship of ACR16. The primary objective is to assess the effects of ACR16 on voluntary motor function in HD subjects. Secondary objectives are to assess the effects of ACR16 on clinical global impression of change (CGI-C), cognitive function, behavior, and symptoms of depression and anxiety at 12 weeks of treatment; in addition to assessing its safety and tolerability.